LDLR and Hepatic steatosis: FXR enhances the expression of the low-density lipoprotein receptor (LDLR) to facilitate cholesterol clearance and suppresses the expression of sterol regulatory element-binding protein-1c (SREBP-1c) to decrease hepatic triglyceride production, thereby promoting fatty acid β-oxidation and mitigating hepatic steatosis [88].